Ken Tawara Email & Phone Number | As a dedicated researcher and scientist during my time at Boise State University, I focused on investigating the impact of inflammatory cytokines, specifically interleukin-6 (IL-6) and oncostatin M (OSM), on breast cancer metastasis. Notably, my research demonstrated the pivotal role of OSM in promoting breast cancer metastasis to the bone, and I successfully demonstrated that reducing OSM levels effectively suppressed bone metastases in mouse models. Building on this foundation, I continued to explore the influence of OSM, IL-6, and other cytokines and growth factors on breast cancer progression and patient outcomes throughout my Ph.D. studies. Additionally, I collaborated with St. Luke's Mountain State Tumor Institute on pre-clinical trials that involved monitoring inflammatory cytokines in breast cancer patients. My expertise spans diverse techniques and methodologies in the field of cancer research. I have hands-on experience with surgical procedures conducted on mouse models to investigate breast cancer progression. Furthermore, I possess proficiency in various laboratory techniques, including CRISPR, sequencing, DNA analysis, western blotting, and tissue culture. During my tenure as a research consultant, I actively contributed to the development of innovative methods, offered training to personnel, and served as a postdoctoral researcher to develop advanced animal models for metastatic breast cancer testing. At Facible, I played a crucial role in the development of a fluorogenic aptamer for the detection of SARS-CoV-2, conducted clinical trials, and effectively managed the resulting data. Additionally, I made significant contributions to the development of a second-generation multi-target diagnostic assay. Throughout my academic and professional journey, I have consistently demonstrated a commitment to cutting-edge research and the advancement of scientific knowledge in the field of cancer biology.

Ken Tawara

As a dedicated researcher and scientist during my time at Boise State University, I focused on inves...
Boise, Idaho, United States

*50 free lookup(s) per month.

No credit card required.

Ken Tawara’s Email kentawara@boisestate.edu

Ken Tawara’s Phone Numbers

Get KEN’s Phone Number (For Free)

Social Media

Ken Tawara’s Location Boise, Idaho, United States

Ken Tawara’s Current Industry Forta

Ken Tawara’s Prior Industry Boise State University | Facible Biodiagnostics | Lionbridge

Not the Ken Tawara you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

Work Experience

Forta

Scientific Writer

2023-10-01 00:00:00 - Present

Boise State University

Research Consultant

2019-02-01 00:00:00 - 2023-09-01 00:00:00

Facible Biodiagnostics

Senior Scientist

2020-07-01 00:00:00 - 2023-03-01 00:00:00

Lionbridge

Hardware/Software Quality Engineer

2006-05-01 00:00:00 - 2006-08-01 00:00:00

Skills

No Skills Available

Languages

No Languages Available

FAQ About Ken Tawara

Ken Tawara is located at
Boise, Idaho, United States

Ken Tawara is a As a dedicated researcher and scientist during my time at Boise State University, I focused on investigating the impact of inflammatory cytokines, specifically interleukin-6 (IL-6) and oncostatin M (OSM), on breast cancer metastasis. Notably, my research demonstrated the pivotal role of OSM in promoting breast cancer metastasis to the bone, and I successfully demonstrated that reducing OSM levels effectively suppressed bone metastases in mouse models. Building on this foundation, I continued to explore the influence of OSM, IL-6, and other cytokines and growth factors on breast cancer progression and patient outcomes throughout my Ph.D. studies. Additionally, I collaborated with St. Luke's Mountain State Tumor Institute on pre-clinical trials that involved monitoring inflammatory cytokines in breast cancer patients. My expertise spans diverse techniques and methodologies in the field of cancer research. I have hands-on experience with surgical procedures conducted on mouse models to investigate breast cancer progression. Furthermore, I possess proficiency in various laboratory techniques, including CRISPR, sequencing, DNA analysis, western blotting, and tissue culture. During my tenure as a research consultant, I actively contributed to the development of innovative methods, offered training to personnel, and served as a postdoctoral researcher to develop advanced animal models for metastatic breast cancer testing. At Facible, I played a crucial role in the development of a fluorogenic aptamer for the detection of SARS-CoV-2, conducted clinical trials, and effectively managed the resulting data. Additionally, I made significant contributions to the development of a second-generation multi-target diagnostic assay. Throughout my academic and professional journey, I have consistently demonstrated a commitment to cutting-edge research and the advancement of scientific knowledge in the field of cancer biology.